Research programme: mTORC1 inhibitors - REVOLUTION Medicines
Alternative Names: bRo5 inhibitorsLatest Information Update: 28 May 2022
At a glance
- Originator REVOLUTION Medicines
- Class Antineoplastics; Small molecules
- Mechanism of Action MTORC1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 21 Apr 2021 Revolution Medicines has patent protection for mTORC1 inhibitors
- 10 Jan 2020 Research programme: mTORC1 inhibitors - REVOLUTION Medicines is available for licensing as of 10 Jan 2020. https://www.revmed.com/pipeline/rmc-5552